Metabolic Effects of Betaine Supplementation

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-01-31

Study Completion Date

2018-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Betaine is important in cellular metabolic pathways. Few epidemiologic studies link betaine levels to diabetes and cardiovascular disease. Small human studies suggest benefit for non-alcoholic liver disease. In this study we will determine if administration of betaine improves metabolic measures, liver fat and/or endothelial function in humans with glucose intolerance who are overweight.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Macronutrients on Hepatic Lipids, Plasma Triglycerides, and Insulin Sensitivity

NCT00523562

Metabolic Syndrome X Liver Diseases

COMPLETED NA

Precision Nutrition and Metabolic Function

NCT04131166

Obesity Insulin Resistance

ACTIVE_NOT_RECRUITING NA

Effect of 4-week Dihydrocapsiate Ingestion on Resting Metabolic Rate

NCT00999297

Obesity Weight

COMPLETED NA

Effects of Lipemia and Metformin on Endothelial Function

NCT01037660

Cardiovascular Disease

COMPLETED EARLY_PHASE1

Effect of Nicotinamide Riboside on Ketosis, Fat Oxidation & Metabolic Rate

NCT06044935

Overweight Obesity

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a single site, prospective, randomized (1:1), double masked, placebo controlled trial to assess metabolic effects of betaine compared to placebo on glycemia and insulin sensitivity, liver fat and endothelial function.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity Dysglycemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Betaine

Group Type ACTIVE_COMPARATOR

Betaine

Intervention Type DRUG

Betaine or placebo administered orally in divided doses over 12 weeks

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo administered orally in divided doses over 3 months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Betaine

Betaine or placebo administered orally in divided doses over 12 weeks

Intervention Type DRUG

Placebo

Placebo administered orally in divided doses over 3 months

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

trimethyl glycine

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\) Men and women aged 21-65 years old;
* 2\) Dysglycemia/prediabetes is defined as impaired fasting glucose (≥100 mg/dl), impaired glucose tolerance (2 hour post 75 g oral glucose load 140-200 mg/dl) or HbA1c 5.7-6.5%);
* 3\) overweight to grade 3 obesity (BMI 25 to 45 kg/m2).

Exclusion Criteria

* 1\) cystathionine beta-synthase (CBS deficiency);
* 2\) Presence of liver disease other than NAFLD;
* 3\) Use of medications causing steatosis;
* 4\) Known alcohol consumption ≥ 2 drink per day;
* 5\) Use of medications known to cause insulin resistance;
* 6\) Use of weight loss drugs (or program) within 3 months of screening;
* 7\) Treatment with any experimental drug within the past 6 months;
* 8\) Subjects must be willing to abstain from use of phosphodiesterase type 5 (PDE-5) inhibitors;
* 9\) Pregnancy or lactation, and women of child bearing potential must use adequate contraception;
* 10\) Surgery within 30 days of screening;
* 11\) Heart disease defined as New York Heart Association Class III or IV cardiac status or hospitalization for congestive heart failure, unstable angina, myocardial infarction, cerebrovascular accident, transient ischemic attack or any revascularization within 6 months;
* 12\) Uncontrolled hypertension;
* 13\) eGFR \<60; 14) History of acquired immune deficiency syndrome;
* 15\) History of malignancy within 5 years;
* 16\) Hemoglobin \<12 g/dL (males), \<10 g/dL (females);
* 17\) Triglycerides (TG) \>500 mg/dL;
* 18\) Poor mental function or any other reason to expect patient difficulty in complying with study requirements;
* 19\) Metal clips or implants that preclude magnetic resonance imaging.

Minimum Eligible Age

21 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No